Biotech Values

[DewDiligence]

As a matter of policy, MNTA does not disclose details of its ANDAs that might help competitors (in this case, MYL). Still, you can read between the lines; if NVS/MNTA were not the party behind the rumored bioequivalence study, Wheeler might simply have denied the rumor instead of giving a no-comment.